Video Module

Clinical Implications of Recent Data on the Community Oncologist

Source: Practice in Evolution: Optimal Management of Colorectal Cancer*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Clinical Implications of Recent Data on the Community Oncologist

Program Chairs: Axel Grothey, MD, Nancy Roach

Faculty:

Al B. Benson III, MD, FACP

CREDIT INFORMATION

Release Date: 11/23/09

Expiration Date: 11/22/10

Physicians: maximum of 1.0 AMA PRA Category 1 Credit™

Registered Nurses: 1.0 Nursing contact hour

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Analyze the role of mismatch repair deficiency in determining therapy for patient with stage II or III colorectal cancer (CRC)
Interpret the role of bevacizumab as adjuvant therapy in patients with stage II or III CRC
Evaluate the relationship between KRAS status and anti-EGFR therapy
Appraise the use of prophylactic skin treatment in patients receiving anti-EGFR therapy
Assess the use of intravenous calcium and magnesium to prevent oxaliplatin-related neurotoxicity

CCO Video Module contain video commentary by our esteemed faculty. Complete the CME posttest and evaluation after watching the presentation.

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.